Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Pharmaceutical Group

www.simcere.com

Latest From Simcere Pharmaceutical Group

Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More

Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.

Asia Pacific Appointments

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business

Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.

Deals Business Strategies

Hisun-Pfizer Split: What Went Wrong And What Next?

The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.

BioPharmaceutical China

Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma

Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Simcere Pharmaceutical Group
  • Senior Management
  • Jinsheng Ren, CEO
    Hua Mu, MD, PhD, CSO
  • Contact Info
  • Simcere Pharmaceutical Group
    Phone: (86) 025 855 66666
    699-18 Xuanwu Ave.
    Nanjing, 210042
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register